CO2023000431A2 - Muteínas de il-10 y proteínas de fusión de las mismas - Google Patents
Muteínas de il-10 y proteínas de fusión de las mismasInfo
- Publication number
- CO2023000431A2 CO2023000431A2 CONC2023/0000431A CO2023000431A CO2023000431A2 CO 2023000431 A2 CO2023000431 A2 CO 2023000431A2 CO 2023000431 A CO2023000431 A CO 2023000431A CO 2023000431 A2 CO2023000431 A2 CO 2023000431A2
- Authority
- CO
- Colombia
- Prior art keywords
- muteins
- antigen
- fusion proteins
- compositions
- trem
- Prior art date
Links
Classifications
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02J—ELECTRIC POWER NETWORKS; CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
- H02J50/00—Circuit arrangements or systems for wireless supply or distribution of electric power
- H02J50/005—Mechanical details of housing or structure aiming to accommodate the power transfer means, e.g. mechanical integration of coils, antennas or transducers into emitting or receiving devices
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Computer Networks & Wireless Communication (AREA)
- Power Engineering (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063045041P | 2020-06-26 | 2020-06-26 | |
| US202063199218P | 2020-12-14 | 2020-12-14 | |
| PCT/US2021/039191 WO2021263167A2 (en) | 2020-06-26 | 2021-06-25 | Il-10 muteins and fusion proteins thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023000431A2 true CO2023000431A2 (es) | 2023-03-27 |
Family
ID=77071744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0000431A CO2023000431A2 (es) | 2020-06-26 | 2023-01-16 | Muteínas de il-10 y proteínas de fusión de las mismas |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230265145A1 (https=) |
| EP (1) | EP4172184A2 (https=) |
| JP (1) | JP2023531493A (https=) |
| KR (1) | KR20230027300A (https=) |
| CN (1) | CN116209459A (https=) |
| AU (1) | AU2021296917A1 (https=) |
| CA (1) | CA3187576A1 (https=) |
| CL (3) | CL2022003755A1 (https=) |
| CO (1) | CO2023000431A2 (https=) |
| CR (1) | CR20230025A (https=) |
| IL (1) | IL299149A (https=) |
| JO (1) | JOP20220348A1 (https=) |
| MX (1) | MX2022016548A (https=) |
| PE (1) | PE20231082A1 (https=) |
| TW (1) | TW202216743A (https=) |
| UY (1) | UY39298A (https=) |
| WO (1) | WO2021263167A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118240058A (zh) * | 2022-12-24 | 2024-06-25 | 广东菲鹏制药股份有限公司 | Il10突变体、融合蛋白和药物 |
| CN116425857B (zh) * | 2023-06-09 | 2023-08-18 | 苏州依科赛生物科技股份有限公司 | 一种无糖基化修饰的il-15及制备方法 |
| CN117143235B (zh) * | 2023-10-26 | 2024-02-09 | 中国科学院苏州纳米技术与纳米仿生研究所 | 一种单克隆抗体及应用 |
| CN121108363A (zh) * | 2024-06-12 | 2025-12-12 | 广东菲鹏制药股份有限公司 | 一种融合蛋白及其用途 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| DE19851675A1 (de) * | 1998-11-10 | 2000-05-11 | Bayer Ag | Menschliche Interleukin-10 Mutantenproteine |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| AU2003280315A1 (en) * | 2002-11-14 | 2004-06-03 | Maxygen, Inc. | Conjugates of interleukin-10 and polymers |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| US20080260820A1 (en) * | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| AU2009290544B2 (en) | 2008-09-12 | 2015-07-16 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| AU2013311606B2 (en) | 2012-09-07 | 2017-10-05 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (TREM-1) Trem-Like Transcript 1 (TLT-1) and uses thereof |
| EP2989240A4 (en) * | 2013-04-24 | 2016-10-19 | Armo Biosciences Inc | INTERLEUKIN-10 COMPOSITIONS AND USES THEREOF |
| PL3369435T3 (pl) * | 2013-07-18 | 2020-04-30 | Xalud Therapeutics, Inc. | Kompozycja do leczenia choroby zapalnej stawów |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| WO2015117930A1 (en) * | 2014-02-06 | 2015-08-13 | F. Hoffmann-La Roche Ag | Interleukine 10 immunoconjugates |
| WO2017152102A2 (en) * | 2016-03-04 | 2017-09-08 | Alector Llc | Anti-trem1 antibodies and methods of use thereof |
| TW201930344A (zh) | 2018-01-12 | 2019-08-01 | 美商安進公司 | 抗ｐｄ-１抗體及治療方法 |
-
2021
- 2021-06-25 PE PE2022003048A patent/PE20231082A1/es unknown
- 2021-06-25 UY UY0001039298A patent/UY39298A/es unknown
- 2021-06-25 EP EP21746606.9A patent/EP4172184A2/en active Pending
- 2021-06-25 US US18/001,913 patent/US20230265145A1/en active Pending
- 2021-06-25 IL IL299149A patent/IL299149A/en unknown
- 2021-06-25 MX MX2022016548A patent/MX2022016548A/es unknown
- 2021-06-25 CN CN202180051906.4A patent/CN116209459A/zh active Pending
- 2021-06-25 WO PCT/US2021/039191 patent/WO2021263167A2/en not_active Ceased
- 2021-06-25 AU AU2021296917A patent/AU2021296917A1/en active Pending
- 2021-06-25 JP JP2022578995A patent/JP2023531493A/ja active Pending
- 2021-06-25 CA CA3187576A patent/CA3187576A1/en active Pending
- 2021-06-25 TW TW110123422A patent/TW202216743A/zh unknown
- 2021-06-25 KR KR1020237003104A patent/KR20230027300A/ko active Pending
- 2021-06-25 CR CR20230025A patent/CR20230025A/es unknown
-
2022
- 2022-12-22 JO JOJO/P/2022/0348A patent/JOP20220348A1/ar unknown
- 2022-12-26 CL CL2022003755A patent/CL2022003755A1/es unknown
-
2023
- 2023-01-16 CO CONC2023/0000431A patent/CO2023000431A2/es unknown
-
2024
- 2024-11-26 CL CL2024003618A patent/CL2024003618A1/es unknown
- 2024-11-26 CL CL2024003619A patent/CL2024003619A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021263167A3 (en) | 2022-04-21 |
| KR20230027300A (ko) | 2023-02-27 |
| CL2024003619A1 (es) | 2025-03-14 |
| UY39298A (es) | 2022-01-31 |
| CR20230025A (es) | 2023-10-05 |
| CL2024003618A1 (es) | 2025-03-14 |
| MX2022016548A (es) | 2023-03-14 |
| CA3187576A1 (en) | 2021-12-30 |
| CN116209459A (zh) | 2023-06-02 |
| CL2022003755A1 (es) | 2023-07-21 |
| PE20231082A1 (es) | 2023-07-17 |
| AU2021296917A1 (en) | 2023-02-02 |
| IL299149A (en) | 2023-02-01 |
| JOP20220348A1 (ar) | 2022-12-22 |
| US20230265145A1 (en) | 2023-08-24 |
| TW202216743A (zh) | 2022-05-01 |
| EP4172184A2 (en) | 2023-05-03 |
| JP2023531493A (ja) | 2023-07-24 |
| WO2021263167A2 (en) | 2021-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023000431A2 (es) | Muteínas de il-10 y proteínas de fusión de las mismas | |
| SA522431672B1 (ar) | Cd3 أجسام مضادة للارتباط بـ | |
| CL2024003661A1 (es) | Anticuerpo anti-trem2 humano; método de producción; y su uso. | |
| CL2021002994A1 (es) | Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos. (divisional de la solicitud no. 201900067) | |
| PE20181451A1 (es) | Anticuerpos neutralizadores del virus de inmunodeficiencia humana | |
| PE20190212A1 (es) | Anticuerpos anti_ige | |
| CO2018005932A2 (es) | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas | |
| PE20211767A1 (es) | Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y metodos de uso de anticuerpos anti-hla-g | |
| MX2015012540A (es) | Ratón de cadena ligera común. | |
| HRP20241498T1 (hr) | Antitijela usmjerena protiv t-staničnog imunoglobulina i mucin proteina 3 (tim-3) | |
| PE20081478A1 (es) | Anticuerpos cd44 | |
| EA201590208A1 (ru) | Усиление активности т-клеток car путем совместного введения биспецифического антитела | |
| EA201491569A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
| EA201600276A1 (ru) | Анти-il-17-антитела, способ их получения и способ применения | |
| HK1208994A1 (en) | Methods for making fully human bispecific antibodies using a common light chain | |
| PE20090993A1 (es) | Anticuerpos anti-cxcr5 humanizados y derivados de los mismos | |
| EA201691925A1 (ru) | Биспецифические антитела, которые связываются с cd38 и cd3 | |
| PH12020551012A1 (en) | Monoclonal antibodies and methods for using same | |
| HRP20200034T1 (hr) | Monoklonska protutijela protiv čimbenika rasta i diferencijacije 15 (gdf-15), te njihova upotreba u liječenju kaheksije uzrokovane rakom i raka | |
| MX353278B (es) | Raton con cadena ligera comun. | |
| MX2015012539A (es) | Ratones que expresan un repertorio limitado de cadena ligera de inmunoglobulina. | |
| EA201590459A1 (ru) | Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение | |
| MX2020006155A (es) | Moleculas de union a cd-16 biespecificas y su uso en el tratamiento de enfermedades. | |
| MY202687A (en) | Pharmaceutical chimeric receptor composition and method thereof | |
| EA202092595A1 (ru) | Антитела к siglec-7 и способы их применения |